Sales & Earnings

Eisai/Biogen’s Alzheimer’s disease medicine Leqembi has been a challenge to launch, but while access to pre-treatment testing has improved, infusion center capacity is impacting US sales.

The Spanish company's Lilly-partnered atopic dermatitis drug is enjoying a decent launch in Germany and in other European countries, "we are getting the price that we wanted," claims CEO Carlos Gallardo.

Hikma says that its acquisition of Xellia’s finished dosage form business and a key contract manufacturing agreement in generics have kept its business on track to meet its full-year forecasts.

After a “solid start to the year”, Organon has delivered on analyst expectations with its third quarter results, despite ongoing questions surrounding future growth and market penetration of key compounds. Meanwhile, the firm’s filing for a biosimilar rival to Prolia/Xgeva has been accepted by the FDA.

Coherus BioSciences will have to weather the storm of supply interruptions for its sole biosimilar product, Udenyca, in the final quarter of 2024.

“The infant formula business is recovering and we've taken actions to simplify and consumerize our business, but there's a lot more work to do,” says CEO Patrick Lockwood-Taylor as Perrigo’s announced latest results.

Biogen has struck another blow against European generic competitors to Tecfidera, after the European Patent Office upheld a dosage patent for the brand that runs until February 2028. Meanwhile, the firm reported flat biosimilars sales in the third quarter of 2024.

While Japanese firms still dominate the money spinners in Asia, companies from China and, lesser so, India are starting to stand out from the crowd.

Lanreotide supply challenges could impact Cipla’s US revenues in the coming quarter, while the firm hopes it can seize emerging opportunities in the GLP-I segment in India, where Novo Nordisk and Eli Lilly are progressing filings for their blockbuster products.

Sandoz has raised its full-year guidance on the back of third-quarter results that saw the firm enjoy growth of more than a tenth, with biosimilars sales up by a whopping 37%.